Meridian Wealth Advisors LLC Buys 99 Shares of Becton Dickinson and Co (BDX)

Share on StockTwits

Meridian Wealth Advisors LLC increased its stake in Becton Dickinson and Co (NYSE:BDX) by 2.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,787 shares of the medical instruments supplier’s stock after acquiring an additional 99 shares during the period. Meridian Wealth Advisors LLC’s holdings in Becton Dickinson and were worth $946,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BDX. Pratt Collard Advisory Partners LLC grew its holdings in shares of Becton Dickinson and by 5.1% during the first quarter. Pratt Collard Advisory Partners LLC now owns 2,078 shares of the medical instruments supplier’s stock valued at $519,000 after buying an additional 100 shares during the last quarter. Investec Asset Management North America Inc. grew its holdings in shares of Becton Dickinson and by 5.1% during the first quarter. Investec Asset Management North America Inc. now owns 11,123 shares of the medical instruments supplier’s stock valued at $2,778,000 after buying an additional 543 shares during the last quarter. Nippon Life Global Investors Americas Inc. grew its holdings in shares of Becton Dickinson and by 10.4% during the fourth quarter. Nippon Life Global Investors Americas Inc. now owns 38,970 shares of the medical instruments supplier’s stock valued at $8,781,000 after buying an additional 3,660 shares during the last quarter. Orrstown Financial Services Inc. grew its holdings in shares of Becton Dickinson and by 6.5% during the first quarter. Orrstown Financial Services Inc. now owns 4,368 shares of the medical instruments supplier’s stock valued at $1,091,000 after buying an additional 267 shares during the last quarter. Finally, Banque Pictet & Cie SA grew its holdings in shares of Becton Dickinson and by 25.0% during the fourth quarter. Banque Pictet & Cie SA now owns 38,524 shares of the medical instruments supplier’s stock valued at $8,680,000 after buying an additional 7,700 shares during the last quarter. Institutional investors own 85.24% of the company’s stock.

Shares of BDX stock opened at $228.36 on Monday. The company has a debt-to-equity ratio of 0.82, a current ratio of 0.96 and a quick ratio of 0.59. Becton Dickinson and Co has a 52 week low of $208.62 and a 52 week high of $265.87. The company has a market capitalization of $61.60 billion, a price-to-earnings ratio of 20.74, a price-to-earnings-growth ratio of 1.71 and a beta of 1.16.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.57 by $0.02. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The company had revenue of $4.20 billion during the quarter, compared to analysts’ expectations of $4.25 billion. During the same quarter last year, the company posted $2.65 EPS. The firm’s revenue was down .6% compared to the same quarter last year. As a group, equities analysts forecast that Becton Dickinson and Co will post 11.7 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Friday, June 7th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Thursday, June 6th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.35%. Becton Dickinson and’s payout ratio is 27.97%.

A number of equities research analysts have recently weighed in on the stock. Barclays boosted their price objective on shares of Becton Dickinson and from $260.00 to $266.00 and gave the company an “equal weight” rating in a report on Monday, April 15th. Zacks Investment Research lowered shares of Becton Dickinson and from a “hold” rating to a “sell” rating in a report on Monday, April 22nd. Wells Fargo & Co lowered their price target on shares of Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating on the stock in a report on Monday, May 13th. TheStreet raised shares of Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday, February 5th. Finally, Morgan Stanley cut their price objective on shares of Becton Dickinson and from $255.00 to $250.00 and set an “equal weight” rating for the company in a report on Friday, May 10th. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Becton Dickinson and currently has a consensus rating of “Buy” and an average target price of $255.31.

In other news, CEO Vincent A. Forlenza sold 11,340 shares of the firm’s stock in a transaction on Monday, February 25th. The shares were sold at an average price of $250.40, for a total value of $2,839,536.00. Following the sale, the chief executive officer now directly owns 227,250 shares in the company, valued at approximately $56,903,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Betty D. Larson sold 1,700 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $224.97, for a total transaction of $382,449.00. Following the completion of the sale, the executive vice president now owns 11,493 shares in the company, valued at $2,585,580.21. The disclosure for this sale can be found here. Insiders sold a total of 31,384 shares of company stock worth $7,901,023 over the last 90 days. Company insiders own 0.12% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4347275/meridian-wealth-advisors-llc-buys-99-shares-of-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: How interest rates affect municipal bond prices

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

$603.70 Million in Sales Expected for ConturaEnergyInc   .  This Quarter
$603.70 Million in Sales Expected for ConturaEnergyInc . This Quarter
Analysts Anticipate Verisign, Inc.  Will Post Quarterly Sales of $306.45 Million
Analysts Anticipate Verisign, Inc. Will Post Quarterly Sales of $306.45 Million
J2 Global Inc  Expected to Post Quarterly Sales of $318.47 Million
J2 Global Inc Expected to Post Quarterly Sales of $318.47 Million
$2.69 Billion in Sales Expected for Iqvia Holdings Inc  This Quarter
$2.69 Billion in Sales Expected for Iqvia Holdings Inc This Quarter
Zacks: Analysts Anticipate CarMax, Inc  Will Announce Quarterly Sales of $5.22 Billion
Zacks: Analysts Anticipate CarMax, Inc Will Announce Quarterly Sales of $5.22 Billion
Zacks: Analysts Anticipate Papa John’s Int’l, Inc.  Will Post Quarterly Sales of $396.88 Million
Zacks: Analysts Anticipate Papa John’s Int’l, Inc. Will Post Quarterly Sales of $396.88 Million


© 2006-2019 Ticker Report